The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines
- 7 October 2021
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 130 (3) , 174-180
Abstract
The recently published 2021 guidelines for the management of patients with anaplastic thyroid cancer from the American Thyroid Association provide updated recommendations and guidance for the treatment of this rare but lethal thyroid cancer and incorporate significant advances since the initial guidelines were published in 2012. In particular, the focus on prompt cytopathologic and immunohistochemical diagnosis with the identification of potentially actionable genomic/molecular targets affirms the central and key role of pathologists and cytopathologists in not only the diagnosis but also the management of these patients.Keywords
This publication has 23 references indexed in Scilit:
- Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 CasesThyroid®, 2017
- Patterns of Treatment Failure in Anaplastic Thyroid CarcinomaThyroid®, 2017
- Management of thyroid cancer: United Kingdom National Multidisciplinary GuidelinesThe Journal of Laryngology & Otology, 2016
- Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancersJournal of Clinical Investigation, 2016
- Undifferentiated (anaplastic) thyroid carcinoma: Practical immunohistochemistry and cytologic look-alikesSeminars in Diagnostic Pathology, 2015
- Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencingHuman Molecular Genetics, 2015
- Targeting RAS–ERK signalling in cancer: promises and challengesNature Reviews Drug Discovery, 2014
- BRAF V600E Inhibition in Anaplastic Thyroid CancerNew England Journal of Medicine, 2013
- PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomasOncology Letters, 2013
- N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomasLaboratory Investigation, 2012